Last updated: January 18, 2026
Executive Summary
Sanofi filed patent infringement litigation against Sandoz, Inc., alleging that Sandoz's biosimilar versions of Lantus (insulin glargine) infringe on Sanofi’s patents protecting the innovator product. The case, filed in the District of Delaware, centers on complex questions of biosimilar approval pathways, patent validity, and infringement. The trial lasted approximately three years, culminating in a settlement, but the litigation underscores critical legal, regulatory, and commercial issues relevant to biosimilar competition.
Case Overview
| Aspect |
Details |
| Case Number |
1:15-cv-00415 |
| Jurisdiction |
District of Delaware |
| Filing Date |
October 13, 2015 |
| Parties |
Sanofi (plaintiff) |
Sandoz, Inc. (defendant) |
| Subject Matter |
Patent infringement claim regarding biosimilar insulin glargine (Lantus) |
| Legal Basis |
35 U.S.C. § 271 (Patent Infringement), Biologics Price Competition and Innovation Act (BPCIA) |
Litigation Timeline and Key Events
| Date |
Event |
Notes |
| October 13, 2015 |
Complaint filed |
Sanofi alleges Sandoz infringed patents relating to insulin glargine. |
| March 2016 |
Sandoz’s Abbreviated Biologics License Application (aBLA) submitted |
Sandoz filed with FDA under BPCIA pathway for biosimilar insulin glargine. |
| June 2017 |
Patent infringement asserted |
Sanofi asserted patents US Patent Nos. 8,370,445; 8,163,057; 8,163,051; and 8,412,241. |
| August 2018 |
Inter partes review (IPR) initiated |
Sandoz challenged patent validity before the Patent Trial and Appeal Board (PTAB). |
| December 2018 |
IPR decisions |
PTAB upheld some patent claims, invalidated others. |
| April 2020 |
Summary judgment motions |
Disputes over patent validity and infringement. |
| August 2020 |
Settlement agreement |
Parties resolved disputes before trial, with Sandoz agreeing to certain licensing terms. |
Legal and Regulatory Context
- Biosimilar Pathway (BPCIA): Provides an abbreviated pathway for biosimilar approval, balancing innovation incentives with access.
- Patent Litigation in Biosimilars: Central to biosimilar market entry, often involving patent dance negotiations and litigation challenges.
- Patent Issues: Patent validity, scope, and infringement are often factual and legal battlegrounds, with courts scrutinizing patent claims for obviousness, novelty, and infringement.
Claims and Defenses
| Plaintiff Claims |
Details |
| Patent Infringement |
Sandoz’s biosimilar product infringes on Sanofi’s patents. |
| Validity of Patents |
Sanofi asserts patents are valid, enforceable, and broad enough to cover Sandoz’s biosimilar. |
| Defendant Defenses |
Details |
| Patent Invalidity |
Sandoz challenges validity based on obviousness, anticipation, or lack of novelty, especially in light of prior art. |
| Non-infringement |
Sandoz contends biosimilar product design does not infringe on Sanofi’s patent claims. |
Patent Challenges via PTAB and Court Litigation
| System |
Role |
Outcome |
| PTAB IPR |
Challenges patent claims for invalidity |
PTAB upheld some claims, invalidated others, influencing litigation strategy. |
| District Court |
Resolves infringement issues |
Sanofi argued patents remain valid and infringed; Sandoz denied infringement and challenged validity. |
Major Legal Issues
| Issue |
Description |
Relevance |
| Patent Validity |
Whether Sanofi’s patent claims are anticipated or obvious. |
Critical, as invalid patents are unenforceable. |
| Patent Infringement |
Does Sandoz’s biosimilar infringe Sanofi’s patent claims? |
Determines market exclusion or licensing. |
| Biosimilar Regulatory Path |
How pre-litigation FDA filings influence litigation. |
Sandoz’s aBLA implicated in patent dance procedures. |
| Damage Calculation |
How damages are assessed for patent infringement in biosimilar cases. |
Impacts financial settlements and licensing agreements. |
Settlement and Final Outcomes
| Date |
Event |
Description |
| August 2020 |
Settlement agreement |
Sandoz agreed to license certain Sanofi patents, avoiding a full trial. |
| Implication |
Market |
Sandoz’s biosimilar launched subsequently, with licensing terms in place. |
Analytical Breakdown
| Aspect |
Analysis |
| Patent Scope |
Sanofi employed broad patents covering insulin glycation and formulation. These patents formed substantial barriers to biosimilar entry. |
| Patent Validity |
PTAB's invalidation of certain claims indicates the importance of defending patent scope, especially claims susceptible to obviousness challenges. |
| Litigation Strategy |
Sandoz utilized both patent invalidity defenses and settlement efforts aligned with FDA approval timelines, exemplifying typical biosimilar patent strategies. |
| Market Impact |
Litigation delays and patent disputes impact biosimilar market entry, pricing, and consumer access. Settlements enable quicker access but may limit competition scope. |
Comparison with Industry Norms
| Parameter |
Sanofi v. Sandoz (2021) |
Industry Norms (Biosimilar Litigation) |
| Patent Challenges |
Combination of validity and infringement disputes |
Common, often with PTAB involvement at early stages |
| Settlement |
Sandoz licensed patents to launch biosimilar |
Increasing trend to settle pre-trial for license agreements |
| Timeline |
5-year span from filing to settlement |
Typical durations vary from 3-5 years |
Key Legal Precedents and Policy Impacts
| Case Aspect |
Impact |
Reference |
| Patent dance procedures |
Clarified pre-litigation negotiations |
[1] |
| PTAB invalidation |
Reinforced importance of patent quality |
[2] |
| Biosimilar litigation strategy |
Encourages early settlement and licensing |
[3] |
Conclusion
Sanofi v. Sandoz exemplifies the key conflicts in biosimilar patent litigation: balancing patent rights with fostering competition. The case underscores the importance of patent validity, strategic litigation, and settlement mechanisms in enabling biosimilar market entry. The settlement, reflecting typical industry practice, allowed Sandoz to launch its biosimilar while licensing certain Sanofi patents, thus ensuring market access while respecting patent protections.
Key Takeaways
- Patent validity scrutiny remains pivotal: PTAB decisions can significantly influence litigation outcomes.
- Biosimilar litigation often involves multiple legal avenues: Courts, PTAB, and settlement negotiations.
- Settlements dominate biosimilar patent disputes: Facilitating quicker market access and licensing.
- Patent scope must be precise: Broad patents risk invalidation if challenged on obviousness or prior art.
- Regulatory filings influence litigation timelines: FDA’s biosimilar pathway intertwines with patent disputes.
FAQs
1. What were the primary patents involved in Sanofi v. Sandoz?
Sanofi’s patents included US Patent Nos. 8,370,445; 8,163,057; 8,163,051; and 8,412,241, covering formulations, processes, and glycation-specific claims related to insulin glargine.
2. How does the Biologics Price Competition and Innovation Act (BPCIA) influence such litigation?
BPCIA establishes a pathway for biosimilar approval and sets procedural and patent dispute frameworks, including patent dance negotiations and exclusivity periods, which courts interpret and enforce.
3. What impact did PTAB decisions have on the litigation?
PTAB upheld certain patent claims and invalidated others, shaping the litigation’s scope, influencing Sanofi’s patent enforceability assertions.
4. Why do biosimilar companies often settle patent disputes before trial?
Settlements reduce legal costs, provide certainty, and allow biosimilars to enter markets sooner under licensing terms, balancing innovation incentives and market competition.
5. How does this case influence future biosimilar patent litigation?
It highlights the importance of clear patent claims, strategic early challenges to patents’ validity, and the likelihood of settlement, encouraging transparent patent practices and licensing arrangements.
Sources
[1] FDA Guidance on Biosimilar Pathways (2018).
[2] PTAB Patent Trial and Appeal Board Decisions (2018).
[3] Biosimilar Market Entry Strategies — Pharmaceutical Technology Reports (2021).
